George Mattheolabakis1, Dandan Ling1, Gulzar Ahmad1, Mansoor Amiji2,3. 1. Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts, USA. 2. Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts, USA. m.amiji@neu.edu. 3. Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. m.amiji@neu.edu.
Abstract
PURPOSE: Cisplatin, is recognized as a first line therapeutic for the treatment of non-small cell lung cancer (NSCLC). Cisplatin resistance is identified as the most detrimental complication during treatment and has been associated with upregulation of several genes, such as the anti-apoptotic gene survivin. In this study, we have evaluated the cytotoxic activity of lipid (C6 and C8)-modified platinum compounds in combination with a survivin-silencing siRNA against cisplatin resistant tumors. METHODS: We synthesized and characterized several lipid-modified platinum compounds and evaluated their cytotoxic activity alone or in combination with survivin-silencing siRNA in vitro and in vivo against A549DDP cells and in vivo in tumor xenograft model. RESULTS: The lipid-modified compounds exhibited significantly stronger cytotoxic activity in vitro compared to cisplatin, with CDDP-C6 and CDDP-C8 producing the most pronounced effect, in both A549 and A549DDP cells. Pre-treatment of the A549DDP cells with survivin-silencing siRNA enhanced the cytotoxic activity of these compounds. In vivo, the co-treatment of the survivin-silencing siRNA and CDDP-C8 produced the strongest tumor growth inhibition effect (64.5%, p < 0.05) on a cancer mouse model of chemoresistant lung cancer. In contrast, cisplatin treatment exhibited no significant tumor growth inhibition (4.5%, no p). CONCLUSIONS: Co-treatment of lipid-modified compounds and survivin-silencing siRNA can constitute a reliable alternative to cisplatin treatment for cisplatin-resistant lung tumors that merit further evaluation.
PURPOSE:Cisplatin, is recognized as a first line therapeutic for the treatment of non-small cell lung cancer (NSCLC). Cisplatin resistance is identified as the most detrimental complication during treatment and has been associated with upregulation of several genes, such as the anti-apoptotic gene survivin. In this study, we have evaluated the cytotoxic activity of lipid (C6 and C8)-modified platinum compounds in combination with a survivin-silencing siRNA against cisplatin resistant tumors. METHODS: We synthesized and characterized several lipid-modified platinum compounds and evaluated their cytotoxic activity alone or in combination with survivin-silencing siRNA in vitro and in vivo against A549DDP cells and in vivo in tumor xenograft model. RESULTS: The lipid-modified compounds exhibited significantly stronger cytotoxic activity in vitro compared to cisplatin, with CDDP-C6 and CDDP-C8 producing the most pronounced effect, in both A549 and A549DDP cells. Pre-treatment of the A549DDP cells with survivin-silencing siRNA enhanced the cytotoxic activity of these compounds. In vivo, the co-treatment of the survivin-silencing siRNA and CDDP-C8 produced the strongest tumor growth inhibition effect (64.5%, p < 0.05) on a cancermouse model of chemoresistant lung cancer. In contrast, cisplatin treatment exhibited no significant tumor growth inhibition (4.5%, no p). CONCLUSIONS: Co-treatment of lipid-modified compounds and survivin-silencing siRNA can constitute a reliable alternative to cisplatin treatment for cisplatin-resistant lung tumors that merit further evaluation.
Authors: Mircea Gabriel Stoleriu; Volker Steger; Migdat Mustafi; Martin Michaelis; Jindrich Cinatl; Wilke Schneider; Andrea Nolte; Julia Kurz; Hans Peter Wendel; Christian Schlensak; Tobias Walker Journal: Eur J Cardiothorac Surg Date: 2014-03-13 Impact factor: 4.191
Authors: Wen Xue; James E Dahlman; Tuomas Tammela; Omar F Khan; Sabina Sood; Apeksha Dave; Wenxin Cai; Leilani M Chirino; Gillian R Yang; Roderick Bronson; Denise G Crowley; Gaurav Sahay; Avi Schroeder; Robert Langer; Daniel G Anderson; Tyler Jacks Journal: Proc Natl Acad Sci U S A Date: 2014-08-11 Impact factor: 11.205
Authors: Shanthi Ganesh; Arun K Iyer; Jan Weiler; David V Morrissey; Mansoor M Amiji Journal: Mol Ther Nucleic Acids Date: 2013-07-30 Impact factor: 10.183
Authors: A K M Nawshad Hossian; Fatema Tuz Zahra; Sagun Poudel; Camille F Abshire; Paula Polk; Jone Garai; Jovanny Zabaleta; Constantinos M Mikelis; George Mattheolabakis Journal: Sci Rep Date: 2021-03-22 Impact factor: 4.379